Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Agendia joins the Personalized Medicine Coalition (PMC)


Amsterdam, the Netherlands September 21st, 2007

Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announces that it has joint the US-based Personalized Medicine Coalition (PMC).

'The PMC is playing a key role in shaping the US public policy on personalized medicine. We are very pleased to be a member of a group that will dramatically impact the treatment of patients in the future. After we got both our first IVDMIA product, MammaPrint(R), as well as our logistical sampling and shipping procedure, RNARetain(R)*, cleared by the FDA we believe it is now time to actively participate in the discussion about the implementation of personalized medicine in the US', said Dr. Bernhard Sixt, CEO of Agendia BV.

Edward Abrahams, Executive Director of the PMC, welcomed the addition of the Netherlands-based personalized medicine company: 'We very much look forward to Agendia's involvement in PMC's activities, in particular its participation in our efforts to shape an appropriate regulatory pathway for personalized medicine products.'

About PMC

The Personalized medicine coalition was publicly launched in November 2004 by more than a dozen leading pharmaceutical, biotechnology, diagnostics and information technology companies, along with major academic centres and governmental agencies. An independent, non-profit group dedicated to advancing the understanding and adoption of personalized medicine concepts and products for the benefit of patients, it represents over 100 members. The Coalition seeks to promote discussion and understanding that will lead to the development of sound public policy on matters that affect the realization of personalized medicine.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)**, is a diagnostic test to identify the origin of a metastasis in a cancer type called 'Cancer of Unknown Primary'. Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation.

Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

* RNARetain(R) is a trademark of Asuragen Inc.
** CupPrint(R) is based on a license to the TUO database of AviaraDx Inc.

Contact Information:
Agendia: Bernhard Sixt, CEO at +31-20 512 9161


Publisher Contact Information:

Agendia BV
+31-20 512 9161
-

Company profile of Agendia BV
Past press releases of Agendia BV.

Data


26,356
Tech investments
From our Online Data Service
17,017
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 15€2.4MMaterials
Nov 14N/AE-Commerce
Nov 14€3.1MMedical devices
Nov 14€4.5MOther Software

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.